CD112 Antibody Binding to Block Immune Checkpoint Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches, such as PD-1/L1 therapy, have limited effectiveness due to high heterogeneity of immune checkpoint ligands in tumors and immune cells, leading to inadequate treatment responses in many patients, necessitating the development of antibodies targeting additional immune checkpoint molecules like CD112.
Innovation Solution
Development of an antibody or antigen-binding fragment that binds to CD112, blocking its interaction with receptors CD112R, TIGIT, and CD226, thereby enhancing the anti-cancer function of immune cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1/L1 immunotherapy is used, then anti-cancer effect is improved, but treatment effectiveness is limited due to high heterogeneity of immune checkpoint ligands
Solution Approach 1:
The patent develops a dual-specific antibody that can simultaneously bind to two different immune checkpoint molecules, enabling a single therapeutic agent to target multiple pathways. This multi-functional approach addresses the heterogeneity problem by providing broad coverage across different tumor types and patient populations, overcoming the limitation of single-target therapies
2Reliability
If immune checkpoint therapy is applied, then immune cell function is enhanced, but tumor heterogeneity leads to inadequate response in many patients
Solution Approach 1:
The patent combines two different antibody specificities into a single molecular entity, creating a dual-specific antibody that targets multiple immune checkpoints simultaneously. This merging strategy allows the therapy to work across diverse tumor types by engaging multiple immune pathways, thereby improving overall response rates while maintaining reliable immune cell activation
3Ease of manufacture
If single-species immune checkpoint antibody is used, then development is simplified, but coverage of all patient populations is insufficient
Solution Approach 1:
The dual-specific antibody design enables a single therapeutic product to serve multiple patient populations by targeting different immune checkpoint molecules. This approach maintains relative manufacturing simplicity while dramatically expanding patient coverage, as the same antibody can treat various tumor types that express different checkpoint ligands
Data Source
AI summary
Provided are an antibody or an antigen-binding fragment thereof and use thereof. The antibody or antigen-binding fragment thereof includes light chain variable region CDRs and heavy chain variable region CDRs. A heavy chain variable region CDR1 sequence is as set forth in GFTFSSYX1, where X1 is Y or M. A heavy chain variable region CDR2 sequence is as set forth in INSQGGST. A heavy chain variable region CDR3 sequence is as set forth in ARSDYDWAWX2AY, where X2 is For Y. A light chain variable region CDR1 sequence is as set forth in QSLLYSSNQKNY. A light chain variable region CDR2 sequence is as set forth in WAX3, where X3 is S or N. A light chain variable region CDR3 sequence is as set forth in QQYYRYPPT.